| Identification | Back Directory | [Name]
Ascomycin | [CAS]
104987-12-4 | [Synonyms]
AAG
FK-520
FR 520
C058028
L 683590
Ascomycin
FR-900520
IMMUNOMYCIN
Changchuanmycin
AscoMycin solution
Tacrolimus USP RC A
Tacrolimus Imprity 6
ASCOMYCIN, STREPTOMYCES HYGROSCOPICUS
Ascomycin:Tacrolimus Desmethylene Impurit
ASCOMYCIN FROM STREPTOMYCESHYGROSCOPICUS VAR ASCOM
ASCOMYCIN, STREPTOMYCES HYGROSCOPICUS VAR ASCOMYCETICUS
ascomycin from streptomyces hygroscopicus var. ascomyceticus
L 683590, FR 900520, IMMunoMycin, FK 520, WS 7238A, NSC 106410
12,18-tetramethyl-,(3s-(3r*(e(1s*,3s*,4s*)),4s*,19s*,26ar*))--10
8-ethyl-3-(2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl)-14,16-dimethoxy
15,19-Epoxy-3H-pyrido(2,1-C)(1,4)oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26A-hexadecahydro-5,19-dihydroxy-3-(2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl)-14,16-dimethoxy-4,10,12,18-tetram
15,19-Epoxy-3H-pyrido2,1-c1,4oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-(1E)-2-(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl-1-methylethenyl-14,16-dimethoxy-4,10,12,18-te | [EINECS(EC#)]
200-835-2 | [Molecular Formula]
C43H69NO12 | [MDL Number]
MFCD06198665 | [MOL File]
104987-12-4.mol | [Molecular Weight]
792.01 |
| Chemical Properties | Back Directory | [Appearance]
White Solid | [Melting point ]
153-157°C | [Boiling point ]
868℃ | [density ]
1.19±0.1 g/cm3(Predicted) | [Fp ]
>110°(230°F) | [storage temp. ]
−20°C
| [solubility ]
≥38.9 mg/mL in DMSO; insoluble in H2O; ≥98.6 mg/mL in EtOH | [form ]
Powder | [pka]
9.97±0.70(Predicted) | [Water Solubility ]
Soluble in DMSO at 65mg/ml; soluble in ethanol at 50mg/m; with warming. Very poorly soluble in water | [InChIKey]
ZDQSOHOQTUFQEM-AMASXYNMSA-N |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Uses]
A potent immunosuppressive agent and could be used as a potential therapeutic agent for autoimmune diseases | [Uses]
Ascomycin is a macrocyclic lactone closely related to tacrolimus and rapamycin. Ascomycin is isolated from several species of Streptomyces and was first reported in 1962. Ascomycin exhibits limited, potent antifungal activity but has found considerable utility as an immunosuppressant. | [Uses]
Ascomycin is a macrocyclic lactone closely related to tacrolimus and rapamycin. Ascomycin is isolated from several species of Streptomyces and was first reported in 1988. Ascomycin exhibits limited, potent antifungal activity but has found considerable utility as an immunosuppressant. | [Uses]
Everolimus is a semi-synthetic macrocyclic lactone prepared from rapamycin by selective alkylation of the 42-hydroxy group with a silyl-protected hydroxyethyl triflate moiety, followed by addition of an ethylhydroxy moiety to provide greater stability and bioavailability. Like all tacrolimus analogues, everolimus binds to receptor protein, FKBP12. The complex then binds to mTOR preventing it from interacting with target proteins. Everolimus is extensively cited in the literature with over 2,000 citations. | [Definition]
ChEBI: A macrolide that is produced by the fermentation of Streptomyces hygroscopicus and exhibits strong immunosuppressant properties. | [Biological Activity]
ascomycin (fk 520, fr900520) is a novel neutral macrolide immunosuppressant, isolated from the cultured broth of streptomyces hygroscopicus subsp. yakushimaensis no. 7238. | [in vitro]
ascomycin (fk 520, fr900520) suppressed lymphocyte reaction in a dose dependent fashion. ascomycin was non-toxic at concentrations less than 3,200 nm, at which the percent inhibition was 18.9%. ascomycin showed antifungal activity against aspergillus fumigatus ifo 5840. ascomycin had no inhibitory effect on bacteria or yeast at 100 μg/ml [1]. | [in vivo]
ascomycin was dose-dependently effective and clearly prolonged skin allograft survival at 3.2 mg/kg or more, though all skin allografts were rejected within 7 days in rats treated intramuscularly with olive oil. ascomycin, dissolved in olive oil, showed no adverse effect when administered intraperitoneally to ddy mice (male, 8 weeks old) at 100 mg/kg [1]. | [target]
peptidyl-prolyl cis-trans isomerase | [storage]
Store at -20°C | [References]
[1] hatanaka h, kino t, miyata s, inamura n, kuroda a, goto t, tanaka h, okuhara m. fr-900520 and fr-900523, novel immunosuppressants isolated from a streptomyces. ii. fermentation, isolation and physico-chemical and biological characteristics. j antibiot (tokyo). 1988;41(11):1592-601. |
|
|